Loading
companiesCompany
Halozyme Therapeutics
Halozyme's recombinant hyaluronidase (ENHANZE) is what lets antibodies such as rituximab, trastuzumab and daratumumab be given as quick under-the-skin injections instead of long infusions; its own tumour-targeting version failed in pancreatic cancer.
Also called: Halozyme Therapeutics, Inc.Halozyme
Overview
Halozyme Therapeutics, founded in 1998 in San Diego, licenses its ENHANZE drug-delivery technology, a recombinant human hyaluronidase that breaks down hyaluronan under the skin so large volumes of antibody can be injected subcutaneously; the subcutaneous forms of rituximab, trastuzumab, daratumumab, pertuzumab and atezolizumab rely on it. Its own PEGylated hyaluronidase PEGPH20, aimed at hyaluronan-rich pancreatic tumours, failed the phase 3 HALO-301 trial in 2019. ClinicalTrials.gov lists Halozyme as lead sponsor of that and other phase 3 trials.
Headquarters
San Diego, CA, US
Scorecard
All companies#52of 1244 companies, score 70
- approved products +18
- targets +6
- modalities +4
- regions +7
- 24-month regulatory events +8
- registry trials +30
- failures -3
3 approved, 0 in phase 3, 0 earlier, 3 targets, 3,583 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
1998
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
ApprovedMonoclonal antibody (anti-CD38)
Daratumumab · Darzalex / Darzalex Faspro (SC)
The CD38 antibody that turned triplets into quadruplets: adding it to standard induction roughly halves the risk of myeloma progressing.
NegativePEGylated recombinant hyaluronidase (stroma-degrading enzyme)
PEGPH20 was designed to break down the hyaluronan that stiffens pancreatic tumours and let chemotherapy in; in the phase 3 HALO-301 trial it raised response rates but not survival, and Halozyme stopped developing it in 2019.
Similar pages
- CompanyLisata Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyMabion
Shares Pivotal (registrational) trial, Clinical trial, Rituximab.
- CompanyNippon Kayaku
Shares Pivotal (registrational) trial, Clinical trial, Trastuzumab.
- CompanyPregLem
- CompanyMedigene
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyAgennix
- CompanyMerrimack Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyImmunitor
cancers
drugs
ApprovedMonoclonal antibody (anti-CD38)
Daratumumab · Darzalex / Darzalex Faspro (SC)
NegativePEGylated recombinant hyaluronidase (stroma-degrading enzyme)
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)